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ABSTRACT
DVDMS-2 is a novel candidate for photodynamic therapy of
tumors. The purpose of the present study was to assess the
distribution and elimination of DVDMS-2 in mice bearing
hepatoma 22 tumors. DVDMS-2 (1, 2 and 4 mg kg1) was
injected intravenously into the mice, extracted from biologi-
cal tissues and quantified using a fluorescence assay. The
data obtained were processed with WinNonlin pharmacoki-
netic software. The fluorescence assay established for
DVDMS-2 quantification was a rapid, reproducible, sensitive
and specific method with good linearity. The pharmacokinet-
ics of DVDMS-2 in tumor-bearing mice conformed to a two-
compartment model. DVDMS-2 accumulated in tumor tissue
to a greater extent than adjacent tissues (skin, muscle) and
sustained a relatively high-level concentration 12 to 24 h fol-
lowing administration, which may be the optimal treatment
time point. In conclusion, DVDMS-2 selectively accumulated
in tumor tissue and was eliminated at a rapid rate in tumor-
bearing mice, suggesting that DVDMS-2 may have few side
effects, including skin phototoxicity. The present study estab-
lished the pharmacokinetic characteristics of DVDMS-2,
which may be beneficial in future clinical study.
INTRODUCTION
Photodynamic therapy (PDT) has been developed as a novel aux-
iliary or alternative to traditional cancer treatment. Compared
with surgery, radiotherapy and chemotherapy, PDT has high
selectivity, is minimally invasive, results in low recurrence rates
and may be used multiple times (1). PDT has been used success-
fully in the clinical treatment of a variety of tumors, including
esophageal (2), bladder (3) head and neck (4) and cervical cancer
(5), particularly superficial cancer (6). PDT relies on a photosen-
sitizing agent and laser light of appropriate wavelength. Photo-
sensitizers selectively accumulate in tumor tissue and react with
laser light, producing reactive oxygen species, including singlet
oxygen. These damage several important cellular structures and
proteins in cancer cells and lead to death (7–10). PDT is there-
fore a promising modality in the noninvasive treatment of
tumors.
Photosensitizing agents serve a key role in PDT. Photofrin
(porfimer sodium) is a first-generation photosensitizer which has
achieved remarkable clinical results in recent decades. However,
a disadvantage associated with Photofrin is skin photosensitivity
that requires patients to avoid light for 4-6 weeks following
treatment. Furthermore, Photofrin is a complex mixture, and sev-
eral of its compounds have not been investigated (11). DVDMS,
separated from Photofrin, is a sodium porphyrin dimer sodium
salt bonded by an ether bond. DVDMS is a heterogeneous mix-
ture of 3 isomers (DVDMS-1, DVDMS-2 and DVDMS-3),
which have equal efficacy (12). However, DVDMS-2, di[1-[6,7-
dipropionic acid sodium 1,3,5,8- tetramethyl 2- vinyl -4- por-
phin] ethyl]ether, is more easily produced and purified and has
higher water solubility than the other two isomers (12).
DVDMS-2 is a single compound with high photodynamic activ-
ity and low skin toxicity that may reduce the side effects associ-
ated with Photofrin. The molecular structure of DVDMS-2 is
presented in Fig. 1. DVDMS-2 absorbs red light at 628 nm and
has been demonstrated to inhibit the growth of tumor cells
in vitro and in vivo (13,14) and to induce cell death (15).
DVDMS-2, also termed sodium porphyrin, is a potential photo-
sensitizer for the treatment of tumors. However, the pharmacoki-
netics of DVDMS-2 remain unclear.
The present study investigated hepatocellular carcinoma in
BALB/c mice using mouse hepatoma 22 (H22) cells. As PDT is
primarily used for the treatment of surface and lumen tumors, a
*Corresponding authors' emails: luofanghong@xmu.edu.cn (Fanghong Luo);
jhyan@xmu.edu.cn (Jianghua Yan) and wuting78@189.cn (Ting Wu)
†These authors contributed equally to this work.
© 2019 American Society for Photobiology
Figure 1. Molecular structure of DVDMS-2. Di[1-[6,7- dipropionic acid
sodium -1,3,5,8- tetramethyl -2- Vinyl -4- porphin] Ethyl]ether.
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subcutaneous tumor model was used. The pharmacokinetics of
DVDMS-2 in tumor-bearing mice was subsequently analyzed
using fluorescence spectroscopy. The results obtained in the pre-
sent study may aid the clinical translation of DVDMS-2.
MATERIALS AND METHODS
Photosensitizer. DVDMS-2 (Qinglong High-Tech Co., Ltd.) was
dissolved in 5 % glucose solution to form a 1 mg mL1 solution and
stored at 20°C until use.
Experimental animals. Female-specific pathogen-free BALB/c mice
were obtained from Shanghai Slac Laboratory Animal Co., Ltd. The mice
were 6-8 weeks old with a mean weight of 25  2 g. A cell suspension
containing 1 9 106 H22 hepatoma cells was subcutaneously injected into
the right axilla of the mice. The animals were administered DVDMS-2
intravenously and protected from light. All experiments were subject to
approval by the Animal Care and Use Committee of Xiamen University.
Method validation of DVDMS-2 determination by a fluorescence
assay. The concentration of DVDMS-2 in biological samples was
determined by a fluorescence assay performed using a LS 55
fluorescence spectrophotometer (Perkin-Elmer, Waltham, Massachusetts)
and a 1 cm quartz cuvette. A wavelength range of 550-750 nm and a slit
width of 5.0 nm were used for both excitation and emission. The
excitation and emission wavelengths were set at 408 and 628 nm,
respectively. The specificity, lower limit of quantification, linearity of the
calibration curve, precision, accuracy, recovery rate and stability
determination of the fluorescence assay were validated.
Plasma pharmacokinetics. Mice with solid tumors were fasted
overnight with free access to water. DVDMS-2 dissolved in 5% glucose
solution was injected into BALB/c mice via the tail vein at three dosages
(1, 2 and 4 mg kg1), and the mice were subsequently kept in the dark.
Blood samples (0.5 mL) were collected from the orbital sinus 5, 10, 20,
30 and 45 min and 1, 2, 6, 12, 24, 48, 72 and 144 h following injection
and stored in heparinized tubes. Five animals were studied at each time
point. The plasma was separated from blood by centrifugation, protected
from light and stored at 20˚C until use.
Tissue distribution. Mice with solid tumors were fasted overnight with
free access to water. DVDMS-2 dissolved in 5% glucose solution was
injected into BALB/c mice via the tail vein at a dose of 2 mg kg1.
Animals were sacrificed by cervical dislocation 5, 10, 20, 30 and 45 min
and 1, 2, 6, 12, 24, 48, 72 and 144 h following injection. The heart, lung,
liver, kidney, spleen, muscle, skin and tumor tissues were removed, rinsed
with saline, blotted dry and stored at 70°C until use. The concentration of
the drug in the tissues was measured by the fluorescence assay, using the
corresponding tissue from untreated mice as a blank control.
Processing of DVDMS-2 plasma samples. A total of 100 µL plasma
was placed into a 5-mL centrifuge tube, followed by the addition of
2.9 mL methanol-PBS (2:1 v/v) extracting solution. The solution was
mixed for 5 min and centrifuged at 2775 g for 30 min. The supernatant
was removed and placed into another centrifuge tube.
Processing of DVDMS-2 biological tissue samples. A total of 100 mg
tissue was placed in a homogenizer, followed by the addition of 1.5 mL
phosphate-buffered saline (PBS 10–2 M; pH = 7.4) and fully
homogenized. A total of 1.0 mL homogenate was removed and placed
into another centrifuge tube. The homogenate was mixed with 2.0 mL
methanol and centrifuged at 2775 g for 30 min. Following centrifugation,
the supernatant was removed and placed into another centrifuge tube.
The concentration of DVDMS-2 in the supernatant was determined by
the fluorescence assay with the excitation and emission wavelengths set
at 408 and 628 nm, respectively.
Data analysis. Data are presented as the mean  standard deviation
(X  S). The pharmacokinetic parameters were obtained using the
WinNonlin practical pharmacokinetic calculation program. OriginLab
software (version 8.1) was used for statistical analysis.
RESULTS
Plasma pharmacokinetics
The level of DVDMS-2 in tumor-bearing mice plasma, represented
by a semilogarithmic plot of mean DVDMS-2 concentration in
plasma vs. time following intravenous injection, is shown in
Fig. 2. The plasma concentration decreased rapidly in the first
12 h, as is expected for intravenous injection.methanol and cen-
trifuged Compartmental model analysis using WinNonlin soft-
ware, residual error analysis, correlation coefficient and Akaike
information criteria revealed that the pharmacokinetics data are
best represented by a two-compartment model. The pharmacoki-
netic parameters are shown in Table 1. DVDMS-2 plasma levels
were described by the following equations: C
(t) = 1.91e0.09t + 12.25e5.92t (r = 0.989) for a dose of
1.0 mg kg1, C(t) = 15.71e5.82t + 5.36e0.16t (r = 0.998) for a
dose of 2.0 mg kg1 and C(t) = 21.37e1.63t + 10.10e0.10t
(r = 0.995) for a dose of 4.0 mg kg1. DVDMS-2 exhibited a
rapid distribution phase and relatively slow elimination phase.
Within the dose range studied, the AUC and C0 were dose-depen-
dent. AUC0!1 ðmg h1 L1Þ ¼ 30:384 doseðmg kg1Þ  10:06
ðr2 ¼ 0:992;P\0:05Þ and C0 ðmg L1Þ ¼ 5:6886 doseðmg kg1Þ
þ8:96 ðr2 ¼ 0:995;P\0:05Þ: Linear regression coefficients were
>0.99, demonstrating a good dose linearity within the dose range used.
Consequently, Cl, t1/2 and distribution volume at steady state (Vss)
were independent of the dose. The Vss (range, 0.31-0.34 L kg1)
and the mean residence time (6.8 h and 8.94 h) suggested that
DVDMS-2 is widely distributed and is rapidly eliminated.
Biodistribution
DVDMS-2 was rapidly distributed to the inner organs and tissues
in mice injected with a single dose of 2 mg kg1 (Figs. 3 and
4). DVDMS-2 biodistribution occurred nonuniformly. The peak
concentration of DVDMS-2 in healthy inner organs was
observed 1-2 h following administration. The peak concentra-
tions in the skin and tumors were observed 6 and 12 h
following administration, respectively. The highest concentra-
tions distributed as follows: Liver > lungs > spleen >
kidneys > heart > tumor > muscle > skin. At a dose of
2 mg kg1, the peak concentration in the lungs (24.78 lg g1)
was ~ 20 times higher than the peak concentration in the skin
(1.14 lg g1).
The concentration of DVDMS-2 had rapidly decreased in tis-
sues including the liver, spleen and lungs, and particularly the lung
and heart, 6 h following administration. At this time, the
Figure 2. Mean plasma time-concentration curves of DVDMS-2 follow-
ing a single intravenous dose of 1, 2 and 4 mg kg1 in mice bearing
hepatoma 22 solid tumors.
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concentration of drug in the lungs had decreased to 40% of the
peak concentration. The concentration of drug in heart was at a
low level.
The concentration of DVDMS-2 was at a low level in the
heart, lungs and kidneys 12 h following administration. The con-
centration of drug in the liver and spleen had decreased to 30%
of the peak concentration. The concentration also decreased in
the muscle and skin; however, the peak concentration was
reached in tumor tissue.
DVDMS-2 was almost completely eliminated in the majority
of tissues 24 h following administration. However, the tumor
drug concentration remained >80% of the peak concentration,
and the tumor-to-normal tissue ratios were 5 and 7 in the skin
and muscle, respectively. DVDMS-2 was completely eliminated
in all tissues 48 h following administration.
Method validation
Specificity. The fluorescence emission spectrum of 200 ng mL1
DVDMS-2 dissolved in PBS presented in Fig. 5 shows a charac-
teristic peak at 631 nm. The fluorescence emission spectrum of
200 ng mL1 DVDMS-2 dissolved in methanol-PBS (2:1 v/v)
presented in Fig. 6 shows a characteristic peak at 628 nm. The
fluorescence peaks of 200 ng mL1 DVDMS-2 in the two sol-
vents were distinct from impurities. As the fluorescence intensity
of DVDMS-2 in methanol-PBS (2:1 v/v) was >70 times higher
than in PBS alone, a mixture of methanol-PBS (2:1 v/v) was
selected as solvent in the current study.
The typical fluorescence spectrums of blank plasma, blank
plasma spiked with DVDMS-2 and mouse plasma sample fol-
lowing the intravenous administration of DVDMS-2 are pre-
sented in Fig. 7. The results suggested that there was a small but
stable interference from endogenous plasma components
(Fig. 7A). However, the fluorescence peaks of DVDMS-2 were
distinguishable from baseline noise.
Lower limit of quantification. The lower limit of quantification of
the fluorescence assay was 10 ng mL1 in biological samples,
based on twice the signal-to-noise ratio with background subtrac-
tion (Fig. 7B).
Linearity of the calibration curve. DVDMS-2 was diluted with
methanol-PBS (2:1 v/v) to produce a series of standard solutions
(0, 10, 20, 40, 80, 100, 200, 400, 800 and 1600 ng mL1). The
fluorescence intensity was measured at excitation and emission
wavelengths of 408 and 628 nm, respectively. The regression
linear equation obtained was y = 0.9967C0.4325, and the cor-
relation coefficient (R) was 0.9996.
Plasma samples. DVDMS-2 was diluted in blank plasma to pro-
duce a series of standard solutions (0, 10, 20, 40, 80, 100, 200,
400, 800 and 1600 ng mL1). The fluorescence intensity of the
standard solutions was measured, and the DVDMS-2 plasma
standard curve was constructed. All the fluorescence intensity
should be eliminated from blank plasma peak effects. The regres-
sion equation of the DVDMS-2 plasma standard curve was
y = 0.6294C-6.4589 (R = 0.9966).
Other biological samples. DVDMS-2 was added to liver tissue
homogenate diluted with methanol-PBS (2:1 v/v) to produce a
series of standard solutions, and the fluorescence intensity was
measured as described for the plasma samples. All the fluores-
cence intensity should be eliminated in blank liver tissue peak
effects. The regression linear equation of the liver standard
curve was y = 0.3726C-0.4071 (R = 0.9961). Standard curves
for the heart, spleen, lungs, kidneys, muscle and skin were
established using the aforementioned method. Good linearity in
the range of 10–1600 ng mL1 was obtained for all tissues with
R > 0.996.
Standard curves, correlation coefficients and the linear ranges
of DVDMS-2 in tissue samples are presented in Table 2 and
Fig. 8.
Accuracy and precision. Six sets of blank plasma and plasma
spiked with DVDMS-2 (10, 50 and 200 ng mL1) were prepared
in order to investigate the precision of the assay. The intraday
accuracy and precision at concentrations of 10, 50 and
200 ng mL1 DVDMS-2 were determined five times per day.
The interday accuracy and precision of DVDMS-2 were deter-
mined five times on three different days.
Intraday and interday accuracy and precision of the DVDMS-
2 concentration in plasma are presented in Table 3. The repro-
ducibility of the methodology was investigated by examining the
intraday and interassay variance. The results revealed that the
intra- and interassay relative standard deviation (RSD) was
<10%.
Table 1. Pharmacokinetic parameters following the intravenous administration of DVDMS-2 at single dose of 1, 2 and 4 mg kg1 in tumor-bearing
mice.
Pharmacokinetic parameters
Dose: 1 mg kg1 Dose: 2 mg kg1 Dose: 4 mg kg1
(n = 5) (n = 5) (n = 5)
Two-compartment model
Initial concentration (C0) (mg L
1) 14.16 21.07 31.47
Half-life of first compartment (t1/2a) (h) 0.11  0.01 0.13  0.02 0.42  0.08
Half-life of second compartment (t1/2b) (h) 7.68  0.54 4.31  0.56 6.82  1.53
Elimination rate constant from the central compartment (K10) (h
1) 0.61  0.08 0.59  0.09 0.27  0.05
Transfer rate constant of compartment 1 to 2 (K12) (h
1) 4.64  0.43 3.78  0.42 0.86  0.12
Transfer rate constant of compartment 2 to 1 (K21) (h
1) 0.89  0.15 1.59  0.13 0.60  0.07
Peak concentration (Cmax) (mg L
1) 14.43  1.91 21.05  1.38 31.47  3.32
Area under curve (AUC0?∞) (mg h
1 L1) 23.51  2.72 45.93  5.08 113.07  10.12
Half-life (t1/2) (h) 1.13  0.12 1.18  0.19 2.49  0.56
Plasma clearance (Cl) (mL h1 kg1) 0.04 0.06 0.04
Mean residence time (MRT) (h) 10.12  1.91 5.77  1.02 8.77  1.73
Distribution volume at steady state (Vss) (mL kg
1) 0.43 0.32  0.03 0.31  0.05
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Recovery rate and stability. The recovery rate of DVDMS-2 was
checked at three quality control levels (10, 50 and 200 ng mL1)
by comparing the fluorescence intensity of DVDMS-2 in
extracted plasma or tissue samples with that of DVDMS-2
directly dissolved in standard solutions at the same concentration
(Table 4). The recovery rates of DVDMS-2 in plasma over the
concentration range of 10–200 ng mL1 ranged between 98.2
and 99.8% with RSD < 5. The recovery rates of DVDMS-2 in
tissues were measured in the same way as described for plasma
samples, and recovery rates of >80% with RSD < 10% were
obtained. DVDMS-2 was recovered in a precise and reproducible
manner during the validation experiments.
At ambient temperature, DVDMS-2 was stable for 24.0 h in
mouse plasma (RSD = 2.58%). DVDMS-2 was stable when
stored at 20°C for a week (RSD = 6.47%).
DISCUSSION
The photosensitizing agent DVDMS-2 is a hydrophilic tetra-
sodium salt that easily dissolves in alkaline solutions such as
PBS (pH 7.4). The peak fluorescence excitation peak of
DVDMS-2 is observed at 408 nm. When using PBS as the sol-
vent, the lower limit of quantification of DVDMS-2 was
100 ng mL1, which was higher than the level of DVDMS-2 in
Figure 3. Concentration of DVDMS-2 in the liver, lungs, spleen, kidneys, heart, muscle and skin of mice bearing hepatoma 22 solid tumors at different
times following a single intravenous dose of 2 mg kg1.
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biological samples, and therefore could not be applied for phar-
macokinetic studies. However, DVDMS-2 dissolved in metha-
nol-PBS (2:1 v/v) exhibits strong fluorescence activity and the
lower limit of quantification for DVDMS-2 in the present study
was 10 ng mL1. In order to increase the sensitivity of the
DVDMS-2 fluorescence assay, an emission wavelength at
628 nm was selected in the present study. The results revealed
that the fluorescence assay using methanol-PBS (2:1 v/v) as sol-
vent was a reproducible, sensitive, accurate and specific method
to quantify DVDMS-2 with high a recovery rate. The method
established in the present study may therefore be applied to
investigate the pharmacokinetics of DVDMS-2.
The standard curves constructed in the present study revealed
that DVDMS-2 exhibited varying fluorescence intensity in differ-
ent tissues; however, good linearity was observed in all tissues.
For the same concentration of DVDMS-2, the highest
fluorescence intensity was observed in serum and skin, and the
lowest in spleen. Differences in fluorescence intensity may occur
as tissues receive varying blood supplies (16). The fluorescence
intensity in all tissues was significantly lower than that observed
in methanol-PBS (2:1 v/v) solution.
The results obtained in the current study revealed that the con-
centration of DVDMS-2 in the plasma peaked immediately after
intravenous injection and was followed by an exponential
decrease. The rate of decline slowed down 6 h following admin-
istration. Concentrations of DVDMS-2 came to a low level 24 h
following administration and almost disappeared after 72 h.
According to the kinetic profile, the plasma elimination of
DVDMS-2 fits a two-compartment model. The t1/2a and t1/2b
were found to be 0.13 h and 5.07 h. Foscan, another photosensi-
tizing agent, exhibits biexponential plasma clearance in mice,
with t1/2a and t1/2b values of 1.3 and 20.9 h (17), suggesting that
DVDMS-2 is more rapidly eliminated than Foscan. The t1/2a and
t1/2b of DVDMS-2 were shorter than the majority of previously
investigated hematoporphyrin derivative drugs. The plasma elimi-
nation kinetics of Photofrin II were consistent with a two-com-
partment model following an intraperitoneal injection of
20 mg kg1, with t1/2a and t1/2b values of 5 and 30 h (18). In
cancer patients, the t1/2b of Photofrin was 250  285 h follow-
ing a single 2 mg kg1 intravenous dose, compared with
415  104 h in healthy subjects (data from the manual of
PHOTOFRIN for Injection). In the present study, DVDMS-2
exhibited rapid distribution and elimination characteristics fol-
lowing intravenous injection in mice and maintained an effective
concentration over the time range of light exposure. These char-
acteristics may reduce the accumulation of drug in normal tissues
and reduce toxicity.
The Vss of DVDMS-2 was <0.4 L kg
1. The Vss of Photofrin
was previously reported to be as high as 2.8 L kg1 (19), sug-
gesting that the distribution of DVDMS-2 was mainly limited to
the systemic circulation and blood-rich organs. In the present
study, the highest drug concentrations were observed in the liver
and lungs, followed by the spleen, kidney and heart. The lowest
Figure 4. Concentration of DVDMS-2 in hepatoma 22 solid tumors at
different times following a single intravenous dose of 2 mg kg1.
Figure 5. Fluorescence emission spectra of 200 ng mL1 DVDMS-2 dissolved in PBS with the characteristic peak at a wavelength of 631 nm.
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Figure 6. Fluorescence emission spectra of 200 ng mL1 DVDMS-2 dissolved in methanol-PBS (2:1 v/v) with the characteristic peak at a wavelength
of 628 nm.
Figure 7. Fluorescence emission spectra of DVDMS-2 in plasma obtained from mice bearing hepatoma 22 solid tumors. The fluorescence excitation
spectrum at an emission wavelength of 408 nm exhibited two peaks at wavelengths of 628 nm and 692 nm, respectively. (A) Fluorescence spectrum of
blank plasma. (B) The lower limit of quantitation of DVDMS-2 (10 ng mL1) in plasma. (C) Fluorescence spectrum of DVDMS-2 spiked in plasma at
a concentration of 200 ng mL1. (D) Fluorescence spectrum of a plasma sample containing 195.8 ng mL1 DVDMS-2 following the intravenous
administration of 2 mg kg1 DVDMS-2.
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concentrations were observed in the skin and muscle. Previous
studies have suggested that photosensitizers accumulate in high
concentrations due to the specific characteristics of the liver
(20,21). Hepatic sinusoidal endothelial cells are highly fenes-
trated and allow molecules to pass through the blood vessels
easily. DVDMS-2 accumulates in the lungs shortly after adminis-
tration. A previous study reported that high doses of photosensi-
tizing agents resulted in pulmonary hemorrhage and acute
interstitial pneumonia (22).
Previous studies demonstrated that several photosensitizers
accumulated in components of the reticuloendothelial system
(23,24), similar to the results obtained in the current study. The
low quantity of DVDMS-2 detected in the skin may decrease the
skin photosensitivity associated with photosensitizing agents
(13,14). In the present study, the accumulation of DVDMS-2 in
tumor tissue gradually increased and peaked 12 h following
administration. The DVDMS-2 concentration in tumors was rela-
tively stable 12 to 24 h following administration and was at least
3.2, 2.9 and 3.3 times higher than that in plasma, skin and mus-
cle, respectively. The tumor-to-normal tissue ratio of DVDMS-2
in the current study was higher than that reported for Photofrin
(1.7  0.7) (25). The goal of PDT is to achieve the optimal anti-
tumor effect while preserving healthy tissues. The results
obtained in the current study suggested that the period between
12 and 24 h following DVDMS-2 administration may be the
optimal exposure time. The optimal exposure period following
the administration of Photofrin in bile duct cancer is 24–48 h
Figure 8. Standard curves of DVDMS-2 in mouse plasma and tissue samples.
Table 2. Standard curves, correlation coefficients and linear ranges of
DVDMS-2 in tissue samples.
Tissue Standard curve
Correlation
coefficients (R2)
Linear ranges
(ng mL1)
Blood y = 0.6294C  6.4589 0.9932 10–1600
Heart y = 0.3394C  3.8409 0.9952 50–400
Liver y = 0.3726C  0.4071 0.9923 25–1600
Spleen y = 0.1574C + 4.9295 0.9977 10–320
Lung y = 0.1985C + 1.179 0.9947 10–1000
Kidney y = 0.3126C  8.8166 0.9984 32–500
Muscle y = 0.4459C  2.119 0.9948 10–200
Skin y = 0.6223C  1.6746 0.9983 10–200
Table 3. Intraday and interday accuracy and precision of DVDMS-2 quantification in mice.
Concentration added (ng mL1)
Intraday
Interday
Concentration obtained (ng mL1)
Mean  SD
Precision
RSD (%)
Accuracy
RE (%)
Precision
RSD (%)
10 10.20  1.00 9.12 1.95 8.87
50 51.73  4.39 8.97 3.46 2.87
200 205.29  6.08 2.76 2.65 4.17
Table 4. The recovery rate of DVDMS-2 in liver tissue.
Concentration added
(ng mL1)
Concentration obtained
(ng mL1)
Mean  SD
Relative
recovery (%)
10 9.64  0.43 96.4
50 48.62  1.90 97.2
200 197.46  3.23 98.7
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(25), suggesting that DVDMS-2 may reduce the period of light
avoidance prior to laser light irradiation.
CONCLUSION
In conclusion, the fluorescence assay established in the present
study was a rapid, constant, sensitive, precise and specific
method to determine DVDMS-2 in biological tissues. The results
indicated that the pharmacokinetics of DVDMS-2 in tumor-bear-
ing mice was consistent with a two-compartment model. The
present study demonstrated that the new novel photosensitizing
agent DVDMS-2 preferentially accumulated in H22 tumors com-
pared with the surrounding normal tissues, exhibited rapid clear-
ance from the circulation system and resulted in relatively minor
toxicity. Furthermore, the results suggested that the period
between 12 and 24 h following administration may be the opti-
mal treatment time point. The results obtained in the present
study may guide future studies investigating the effects of
DVDMS-2 in vivo.
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